An autoinjector is a medical device that is used to deliver a specific medicine dose. These injectors were designed to overcome the fear of self-administration of a needle-based drug delivery method. The home care setting accounted for the largest share of the entire Autoinjectors Market in terms of end-user. It currently holds approximately 52% of the market and is expected to continue to do so throughout the estimated period of 2022-2028.

Furthermore, in the year 2020, North America owned the greatest share of the global Autoinjectors market, accounting for approximately 41% of the total. However, over the forecasted period of 2022-2028, the Asia-Pacific region is expected to be the fastest-growing area of the market.

Access Full report here : https://www.zionmarketresearch.com/report/autoinjectors-market

The following is the segmentation outline from Zion Market Research's recent study on the Autoinjectors Market:

By Type

● Reusable Autoinjectors
● Disposable Autoinjectors

By Application

● Hospitals & Clinics
● Home Care Settings
● Ambulatory Care Settings

Regions

● North America
● Europe
● Asia-Pacific
● LAMEA

The Autoinjectors Market is expected to grow at a CAGR of 17.9% from USD 46.0 billion in 2022 to USD 238.7 billion by the end of 2028, from USD 46.0 billion in 2022. Anaphylaxis is becoming more common, and rapid technological advancements in the autoinjectors industry are accelerating the global market. Anaphylaxis is a condition in which patients experience a potentially fatal allergic reaction to medicines, latex, or Hymenoptera stings. Anaphylaxis is usually treated with an adrenaline autoinjector. According to National Institute for Health and Care Excellence (NICE) studies, anaphylaxis is a very frequent illness, occurring in 1 out of every 1333 instances.

The Rheumatoid Arthritis market segment has the largest share of the market in terms of therapy

The entire market is divided into Anaphylaxis, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and Other Therapies categories based on therapy. The Rheumatoid Arthritis market sector accounted for the biggest share of the overall Global Autoinjectors Market among these therapies. It is mostly attributable to the rise in the number of persons suffering from arthritis. Between 1980 and 2019, the global prevalence of Rheumatoid Arthritis was roughly 460 per 100,000 people, according to the National Library of Medicine.

North America commanded the highest regional share of the Global Autoinjectors Market, followed by Asia Pacific. North America currently holds a 41 percent share of the global market. Throughout the anticipated period, it is expected to increase at a CAGR of 19-22 percent. Its dominance is due to a growth in the rate of chronic diseases and autoimmune disorders. According to the National Stem Cell Foundation (NSCF), more than 80 different forms of autoimmune disorders afflict roughly 4% of the world's population. Multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, psoriasis, Cohn's disease, and scleroderma are the most common of these disorders.

The major players that are covered in the Global Autoinjectors Market report are:

• GlaxoSmithKline plc
• Merck KGaA
• Johnson & Johnson
• Dickinson and Company
• AbbVie Inc
• Eli Lilly and Company
• Antares Pharma
• Amgen
• Ypsomed
• Mylan
• Teva Pharmaceutical

Read more at : https://www.zionmarketresearch.com/news/autoinjectors-market

Global Autoinjectors Market: Recent Developments

➜ The US FDA (Food and Drug Administration) granted Antares Pharma, a speciality pharmaceutical firm, fast track designation for ATRS-1902 in January 2022. The ATRS1902 development programme aided a suggested indication for the overall treatment of acute adrenal insufficiency in adults and adolescents, utilising the Vai new proprietary autoinjector technology to deliver a stable liquid hydrocortisone formulation.

➜ Owen Mumford announced Aidatus, a two-step mechanism autoinjector device that can accommodate 1mL and 2.25 mL prefilled glass syringes, in September 2021. Aidatus is the first autoinjector to be designed that can hold two distinct prefilled volumes in the same device, reducing complexity and boosting patient satisfaction.

➜ XYOSTED, Saudi Arabia's supply and regulatory approval body, approved Antares Pharma and Lunatus Global's deal in August 2020. According to the agreement, Antares Pharma will be in charge of manufacturing and packaging, while Lunatus Global will be in charge of approvals, promotion, and distribution.

About Us :

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.